Canada - English - Health Canada

lupin pharma canada limited - cephalexin (cephalexin monohydrate) - powder for suspension - 125mg - cephalexin (cephalexin monohydrate) 125mg - first generation cephalosporins

Canada - English - Health Canada

lupin pharma canada limited - cephalexin (cephalexin monohydrate) - powder for suspension - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Canada - English - Health Canada

lupin pharma canada limited - cephalexin (cephalexin monohydrate) - tablet - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Canada - English - Health Canada

lupin pharma canada limited - cephalexin (cephalexin monohydrate) - tablet - 500mg - cephalexin (cephalexin monohydrate) 500mg - first generation cephalosporins

United States - English - NLM (National Library of Medicine)

lupin limited - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - ethinyl estradiol 0.03 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. na - not available combination oral contraceptives should not be used in women with any of the following conditions: thrombophlebitis or thromboembolic disorders. a past history of deep-vein thrombophlebitis or thromboembolic disorders. cerebral-vascular or coronary-artery disease. thrombogenic valvulopathies. thrombogenic rhythm disorders. diabetes with vascular involvement. uncontrolled hypertension. known or suspected carcinoma of the breast. carcinoma of the endometrium or other known or suspecte

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - amlodipine besilate, quantity: 13.868 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate - hypertension: amlodipine-lupin tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine-lupin tablets are indicated for the first line treatment of chronic stable angina. amlodipine-lupin may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - amlodipine besilate, quantity: 6.934 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate - hypertension: amlodipine-lupin tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine-lupin tablets are indicated for the first line treatment of chronic stable angina. amlodipine-lupin may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 2 mg - capsule - excipient ingredients: lactose monohydrate; povidone; sodium stearylfumarate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 1 mg - capsule - excipient ingredients: maize starch; sodium stearylfumarate; povidone; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; sodium stearylfumarate; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].